28,565 Abbott Laboratories $ABT Shares Sold by Villere ST Denis J & Co. LLC

Posted by Stanley Muller on Nov 10th, 2026

Villere ST Denis J & Co. LLC lowered its holdings in Abbott Laboratories (NYSE:ABT – Free Report) by 13.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 180,259 shares of the healthcare product maker’s stock after selling 28,565 shares during the quarter. Abbott Laboratories accounts for 1.8% of Villere ST Denis J & Co. LLC’s holdings, making the stock its 21st biggest position. Villere ST Denis J & Co. LLC’s holdings in Abbott Laboratories were worth $17,815,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Manning & Napier Advisors LLC acquired a new position in Abbott Laboratories during the second quarter valued at $31,000. Foresight Capital Management Advisors Inc. purchased a new stake in Abbott Laboratories in the third quarter valued at $31,000. Balance Wealth Partners LLC acquired a new stake in Abbott Laboratories during the 3rd quarter worth about $34,000. Summit Securities Group LLC grew its position in Abbott Laboratories by 41.3% during the 2nd quarter. Summit Securities Group LLC now owns 404 shares of the healthcare product maker’s stock worth $37,000 after purchasing an additional 118 shares during the period. Finally, Addison Advisors LLC purchased a new position in shares of Abbott Laboratories during the 2nd quarter valued at about $40,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, EVP Mary Moreland sold 3,500 shares of the stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $116.00, for a total transaction of $406,000.00. Following the transaction, the executive vice president owned 100,791 shares in the company, valued at approximately $11,691,756. This represents a 3.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on ABT. BTIG Research decreased their price objective on Abbott Laboratories from $134.00 to $125.00 and set a “buy” rating for the company in a report on Thursday, October 22nd. Wall Street Zen raised Abbott Laboratories from a “hold” rating to a “buy” rating in a report on Saturday, October 24th. Citigroup reduced their price target on Abbott Laboratories from $125.00 to $122.00 and set a “buy” rating for the company in a research report on Thursday, October 22nd. UBS Group reduced their price target on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a research report on Tuesday, July 28th. Finally, TD Cowen decreased their price target on Abbott Laboratories from $135.00 to $118.00 and set a “buy” rating for the company in a report on Thursday, October 22nd. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $118.32.

Get Our Latest Report on Abbott Laboratories

Abbott Laboratories Stock Up 0.4%

ABT opened at $110.41 on Tuesday. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $132.02. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. The company has a fifty day moving average of $103.99 and a two-hundred day moving average of $101.72. The stock has a market capitalization of $191.04 billion, a price-to-earnings ratio of 41.20, a PEG ratio of 2.02 and a beta of 0.54.

Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.42. Abbott Laboratories had a net margin of 9.75% and a return on equity of 17.97%. The business had revenue of $13.01 billion for the quarter, compared to analyst estimates of $12.99 billion. During the same period in the prior year, the company posted $1.30 EPS. The company’s revenue for the quarter was up 14.5% on a year-over-year basis. On average, research analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. Abbott Laboratories’s dividend payout ratio is presently 94.03%.

Abbott Laboratories Profile

(Free Report)

Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings.

Abbott’s offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac.